CXCL8 and triple-negative breast carcinoma: Previous studies have shown that in triple-negative breast cancer, paclitaxel can promote stem cell phenotype by inducing the secretion of IL-8 while inhibiting the activation of NF-κB can reduce the production of cancer stem cells (CSCs).10